The Sartorius & Science Prize is no longer being offered.
About the Prize
The Sartorius & Science Prize for Regenerative Medicine & Cell Therapy is an annual prize geared toward researchers focused on basic or translational research that advances regenerative medicine and cell therapy; for example cell-, gene-, or immunotherapy, tissue engineering, and materials engineering. Established in 2017, the prize is awarded for outstanding research performed by the applicant and as described in a 1,000 word essay.
The winner of the Sartorius & Science Prize for Regenerative Medicine & Cell Therapy is awarded US$25,000 and publication of his or her essay in Science. The Grand Prize essay and that of the Runner-up are also published on Science Online. The award is announced and presented at a ceremony for which Sartorius will provide financial support to help enable the grand prize winner to attend the ceremony.
The American Association for the Advancement of Science (AAAS) is the world's largest general scientific society, and publisher of the journals, Science, Science Translational Medicine, Science Signaling, Science Advances, Science Immunology, and Science Robotics. AAAS was founded in 1848, and includes some 254 affiliated societies and academies of science, serving 10 million individuals. Science, founded by Thomas Edison, has the largest paid circulation of any peer-reviewed general science journal in the world, with an estimated total readership of more than 400,000.
The non-profit AAAS—www.aaas.org—is open to all and fulfills its mission to "advance science and serve society" through initiatives in science policy, international programs, science education, and more. Science's daily online news is always free to the public, as are editorials, any paper with broad public health significance, and all research articles 12 months after publication. Science further participates in various efforts to provide free access for scientists in the world's poorest countries.
The Sartorius Group is a leading international pharmaceutical and laboratory equipment provider with two divisions: Bioprocess Solutions (BPS) and Lab Products & Services (LPS). Want to hear more about our products and services? Take a moment to sign up for our e-newsletter and get up-to-date info on the newest innovations.
Biopharmaceuticals are manufactured using living cells in complex, lengthy and expensive procedures. BPS focuses on single-use solutions which help customers produce biotech medications and vaccines safely and efficiently. In fact, Sartorius has been pioneering and setting the standard for single-use products which are extensively used in all biopharmaceutical manufacturing processes.
Backed by an extensive offering of premium laboratory instruments, consumables and services, the LPS division concentrates on serving the needs of laboratories performing research and quality assurance at pharma and biopharma companies and on those in academic research institutes. Through strategic acquisitions, our portfolio was further developed to suit the emerging needs and complexities of the regenerative medicine and cell therapy industry. LPS’s innovative bioanalytical tools help scientists answer fundamental and complex biological questions. Sartorius focuses on fast, multiplex cell, protein and virus analysis quantification, on the end-to-end production platforms for cell expansion and harvesting, and on the crucial safety aspects of quality control.
Founded in 1870, Sartorius earned sales revenue of more than 1.56 billion euros in 2018. Approximately 8,125 people work at the Group's 60 manufacturing and sales sites, serving customers around the globe.